{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT04877613",
            "orgStudyIdInfo": {
                "id": "IRB# 848848; UPCC# 12320"
            },
            "organization": {
                "fullName": "University of Pennsylvania",
                "class": "OTHER"
            },
            "briefTitle": "GFR\u03b14 CAR T Cells in MTC Patients",
            "officialTitle": "Phase I Trial of GFR\u03b14 CAR T Cells in Adult Patients With Recurrent or Metastatic Medullary Thyroid Cancer",
            "therapeuticArea": [
                "Oncology and Hematology"
            ],
            "study": "car-t-cells-in-mtc-patients"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-06",
            "overallStatus": "RECRUITING",
            "startDateStruct": {
                "date": "2021-08-19",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2039-06-01",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2039-06-01",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2021-05-03",
            "studyFirstSubmitQcDate": "2021-05-03",
            "studyFirstPostDateStruct": {
                "date": "2021-05-07",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-06-24",
            "lastUpdatePostDateStruct": {
                "date": "2024-06-26",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "University of Pennsylvania",
                "class": "OTHER"
            }
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "This is an open-label phase 1 study to assess the safety and feasibility of autologous T cells expressing a single-chain scFv targeting GFR\u03b14 with tandem TCR/CD3\u03b6 and 4-1BB (TCR\u03b6/4-1BB) co-stimulatory domains (referred to as \"CART-GFRa4 cells\") in patients with incurable medullary thyroid cancer (MTC)."
        },
        "conditionsModule": {
            "conditions": [
                "Metastatic Medullary Thyroid Cancer"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1"
            ],
            "designInfo": {
                "allocation": "NON_RANDOMIZED",
                "interventionModel": "SEQUENTIAL",
                "interventionModelDescription": "The is a Phase I dose finding study to determine the safety of CART-GFRa4 cells. Dose escalation and determination of maximum tolerated dose (MTD) will be based on the standard 3+3 design to explore 3 possible dose levels.",
                "primaryPurpose": "HEALTH_SERVICES_RESEARCH",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 18,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Cohort 1: single dose of 5x10^7 CART-GFRa4 cells via intravenous infusion",
                    "type": "EXPERIMENTAL",
                    "interventionNames": [
                        "Drug: single dose of CART-GFRa4 cells",
                        "Drug: Fludarabine",
                        "Drug: Cyclophosphamide"
                    ]
                },
                {
                    "label": "Cohort -1: single dose of 2x10^7 CART-GFRa4 cells via intravenous infusion",
                    "type": "EXPERIMENTAL",
                    "interventionNames": [
                        "Drug: single dose of CART-GFRa4 cells",
                        "Drug: Fludarabine",
                        "Drug: Cyclophosphamide"
                    ]
                },
                {
                    "label": "Cohort 2: single dose of 1x10^8 CART-GFRa4 cells via intravenous infusion",
                    "type": "EXPERIMENTAL",
                    "interventionNames": [
                        "Drug: single dose of CART-GFRa4 cells",
                        "Drug: Fludarabine",
                        "Drug: Cyclophosphamide"
                    ]
                },
                {
                    "label": "Cohort 3: single fixed dose of 3x10^8 CART-GFRa4 cells via intravenous infusion",
                    "type": "EXPERIMENTAL",
                    "interventionNames": [
                        "Drug: single dose of CART-GFRa4 cells",
                        "Drug: Fludarabine",
                        "Drug: Cyclophosphamide"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "single dose of CART-GFRa4 cells",
                    "description": "Intravenous infusion of lentiviral transduced autologous T cells that have been engineered to express an extracellular single chain antibody (scFv) with specificity towards GFRa4 with fludarabine and cyclophosphamide.",
                    "armGroupLabels": [
                        "Cohort -1: single dose of 2x10^7 CART-GFRa4 cells via intravenous infusion",
                        "Cohort 1: single dose of 5x10^7 CART-GFRa4 cells via intravenous infusion",
                        "Cohort 2: single dose of 1x10^8 CART-GFRa4 cells via intravenous infusion",
                        "Cohort 3: single fixed dose of 3x10^8 CART-GFRa4 cells via intravenous infusion"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Fludarabine",
                    "description": "Lyphodepletion",
                    "armGroupLabels": [
                        "Cohort -1: single dose of 2x10^7 CART-GFRa4 cells via intravenous infusion",
                        "Cohort 1: single dose of 5x10^7 CART-GFRa4 cells via intravenous infusion",
                        "Cohort 2: single dose of 1x10^8 CART-GFRa4 cells via intravenous infusion",
                        "Cohort 3: single fixed dose of 3x10^8 CART-GFRa4 cells via intravenous infusion"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Cyclophosphamide",
                    "description": "Lyphodepletion",
                    "armGroupLabels": [
                        "Cohort -1: single dose of 2x10^7 CART-GFRa4 cells via intravenous infusion",
                        "Cohort 1: single dose of 5x10^7 CART-GFRa4 cells via intravenous infusion",
                        "Cohort 2: single dose of 1x10^8 CART-GFRa4 cells via intravenous infusion",
                        "Cohort 3: single fixed dose of 3x10^8 CART-GFRa4 cells via intravenous infusion"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Incidence of Treatment-Emergent Adverse Events as assessed by CTCAE v5.0.",
                    "timeFrame": "15 years"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Percentage of manufacturing products that meet release criteria.",
                    "timeFrame": "3 months"
                },
                {
                    "measure": "Number of subjects who have a response",
                    "timeFrame": "12 months"
                },
                {
                    "measure": "Best Overall Response (BOR)",
                    "timeFrame": "12 months"
                },
                {
                    "measure": "Duration of Response (DOR)",
                    "timeFrame": "12 months"
                },
                {
                    "measure": "Overall survival (OS)",
                    "timeFrame": "12 months"
                },
                {
                    "measure": "Progression-free survival (PFS)",
                    "timeFrame": "12 months"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n1. Signed, written informed consent\n2. Male or female age \u2265 18 years\n3. Histologically or cytologically confirmed diagnosis of medullary thyroid cancer (MTC).\n4. Incurable recurrent/metastatic disease that is progressive after at least 1 prior tyrosine kinase inhibitor (TKI) containing regimen, or the patient was intolerant of or declined such therapy.\n5. Adequate organ function defined as:\n\n   1. Serum creatinine \u2264 2.5 mg/dl or estimated creatinine clearance \u2265 30 ml/min and not on dialysis.\n   2. AST \u2264 5x upper limit of normal range and total bilirubin \u2264 2.0 mg/dl; except for patients in whom hyperbilirubinemia is attributed to Gilbert's syndrome.\n   3. Left Ventricular Ejection Fraction (LVEF) \u2265 45% confirmed by ECHO/MUGA\n   4. Must have a minimum level of pulmonary reserve defined as \u2264 Grade 1 dyspnea and pulse oxygen \\> 92% on room air\n6. ECOG Performance Status that is either 0 or 1.\n7. Toxicities from prior therapies must have recovered to grade \u2264 2 according to the CTCAE 5.0 criteria or to the patient's prior baseline.\n8. Patients must have evaluable disease as defined by RECIST 1.1.\n9. Subjects of reproductive potential must agree to use acceptable birth control methods.\n\nExclusion Criteria:\n\n1. Evidence of active hepatitis B or hepatitis C infection.\n2. Any other active, uncontrolled infection.\n3. Any prior history of moderate to severe (Grade 2 or higher) pneumonitis.\n4. Subjects with chronic kidney disease with Grade 2 or higher renal impairment (eGFR or CrCl 59-30 ml/min/1.73 m2).\n5. Class III/IV cardiovascular disability according to the New York Heart Association Classification.\n6. Clinically apparent arrhythmia or arrhythmias that are not stable on medical management within two weeks of physician-investigator confirmation of eligibility.\n7. Planned concurrent treatment with systemic high dose corticosteroids. Patients may be on a stable low dose of steroids (\u226410mg equivalent of prednisone). Use of inhaled steroids is allowable. Corticosteroid treatment as anti-emetic prophylaxis on the day of lymphodepleting chemotherapy administration is allowed per institutional practice.\n8. Any moderate to severe skin rash or allergies requiring systemic treatment.\n9. Receipt of immune checkpoint inhibitors within 2 months prior to physician-investigator confirmation of eligibility - Retired with Protocol Version 3.\n10. Pregnant or nursing (lactating) women.\n11. Active autoimmune disease requiring systemic immunosuppressive treatment equivalent to \u2265 10mg daily of prednisone. Patients with autoimmune neurological diseases (such as MS or Parkinson's) will be excluded.\n12. Have any history of prior or active central nervous system (CNS) involvement (e.g., leptomeningeal disease, parenchymal masses) with MTC. Screening for this (e.g., with lumbar puncture and/or brain MRI) is not required unless suspicious symptoms and/or radiographic findings are present. Subjects with calvarial metastatic disease that extends intracranially and involves the dura will be excluded, even if CSF is negative for MTC.\n13. Known seizure disorder or history of prior seizures requiring medication.\n14. History of allergy or hypersensitivity to study product excipients (human serum albumin, DMSO, and Dextran 40).",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Abramson Cancer Center Clinical Trials Service",
                    "role": "CONTACT",
                    "phone": "855-216-0098",
                    "email": "PennCancerTrials@careboxhealth.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Roger Cohen, MD",
                    "affiliation": "University of Pennsylvania",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "University of Pennsylvania",
                    "status": "RECRUITING",
                    "city": "Philadelphia",
                    "state": "Pennsylvania",
                    "zip": "19104",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Abramson Cancer Center Clinical Trials Service",
                            "role": "CONTACT",
                            "phone": "855-216-0098",
                            "email": "PennCancerTrials@careboxhealth.com"
                        }
                    ],
                    "geoPoint": {
                        "lat": 39.95233,
                        "lon": -75.16379
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000013964",
                    "term": "Thyroid Neoplasms"
                },
                {
                    "id": "D000018278",
                    "term": "Carcinoma, Neuroendocrine"
                }
            ],
            "ancestors": [
                {
                    "id": "D000013959",
                    "term": "Thyroid Diseases"
                },
                {
                    "id": "D000004700",
                    "term": "Endocrine System Diseases"
                },
                {
                    "id": "D000004701",
                    "term": "Endocrine Gland Neoplasms"
                },
                {
                    "id": "D000009371",
                    "term": "Neoplasms by Site"
                },
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                },
                {
                    "id": "D000006258",
                    "term": "Head and Neck Neoplasms"
                },
                {
                    "id": "D000018358",
                    "term": "Neuroendocrine Tumors"
                },
                {
                    "id": "D000017599",
                    "term": "Neuroectodermal Tumors"
                },
                {
                    "id": "D000009373",
                    "term": "Neoplasms, Germ Cell and Embryonal"
                },
                {
                    "id": "D000009370",
                    "term": "Neoplasms by Histologic Type"
                },
                {
                    "id": "D000000230",
                    "term": "Adenocarcinoma"
                },
                {
                    "id": "D000002277",
                    "term": "Carcinoma"
                },
                {
                    "id": "D000009375",
                    "term": "Neoplasms, Glandular and Epithelial"
                },
                {
                    "id": "D000009380",
                    "term": "Neoplasms, Nerve Tissue"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M14850",
                    "name": "Recurrence",
                    "relevance": "LOW"
                },
                {
                    "id": "M16718",
                    "name": "Thyroid Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M16723",
                    "name": "Thyroid Neoplasms",
                    "asFound": "Thyroid Cancer",
                    "relevance": "HIGH"
                },
                {
                    "id": "M5534",
                    "name": "Carcinoma",
                    "relevance": "LOW"
                },
                {
                    "id": "M20423",
                    "name": "Carcinoma, Neuroendocrine",
                    "asFound": "Medullary Thyroid Cancer",
                    "relevance": "HIGH"
                },
                {
                    "id": "M7862",
                    "name": "Endocrine System Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M7863",
                    "name": "Endocrine Gland Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M9348",
                    "name": "Head and Neck Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M20495",
                    "name": "Neuroendocrine Tumors",
                    "relevance": "LOW"
                },
                {
                    "id": "M19845",
                    "name": "Neuroectodermal Tumors",
                    "relevance": "LOW"
                },
                {
                    "id": "M20388",
                    "name": "Neuroectodermal Tumors, Primitive",
                    "relevance": "LOW"
                },
                {
                    "id": "M12318",
                    "name": "Neoplasms, Germ Cell and Embryonal",
                    "relevance": "LOW"
                },
                {
                    "id": "M12315",
                    "name": "Neoplasms by Histologic Type",
                    "relevance": "LOW"
                },
                {
                    "id": "M3585",
                    "name": "Adenocarcinoma",
                    "relevance": "LOW"
                },
                {
                    "id": "M12320",
                    "name": "Neoplasms, Glandular and Epithelial",
                    "relevance": "LOW"
                },
                {
                    "id": "M12325",
                    "name": "Neoplasms, Nerve Tissue",
                    "relevance": "LOW"
                },
                {
                    "id": "T5651",
                    "name": "Thyroid Cancer, Medullary",
                    "asFound": "Medullary Thyroid Cancer",
                    "relevance": "HIGH"
                },
                {
                    "id": "T4091",
                    "name": "Neuroendocrine Tumor",
                    "relevance": "LOW"
                },
                {
                    "id": "T4092",
                    "name": "Neuroepithelioma",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC19",
                    "name": "Gland and Hormone Related Diseases"
                },
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "D000003520",
                    "term": "Cyclophosphamide"
                },
                {
                    "id": "C000024352",
                    "term": "Fludarabine"
                }
            ],
            "ancestors": [
                {
                    "id": "D000007166",
                    "term": "Immunosuppressive Agents"
                },
                {
                    "id": "D000007155",
                    "term": "Immunologic Factors"
                },
                {
                    "id": "D000045505",
                    "term": "Physiological Effects of Drugs"
                },
                {
                    "id": "D000018501",
                    "term": "Antirheumatic Agents"
                },
                {
                    "id": "D000018906",
                    "term": "Antineoplastic Agents, Alkylating"
                },
                {
                    "id": "D000000477",
                    "term": "Alkylating Agents"
                },
                {
                    "id": "D000045504",
                    "term": "Molecular Mechanisms of Pharmacological Action"
                },
                {
                    "id": "D000000970",
                    "term": "Antineoplastic Agents"
                },
                {
                    "id": "D000019653",
                    "term": "Myeloablative Agonists"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M6727",
                    "name": "Cyclophosphamide",
                    "asFound": "Effect of",
                    "relevance": "HIGH"
                },
                {
                    "id": "M4225",
                    "name": "Antibodies",
                    "relevance": "LOW"
                },
                {
                    "id": "M10184",
                    "name": "Immunoglobulins",
                    "relevance": "LOW"
                },
                {
                    "id": "M283230",
                    "name": "Fludarabine",
                    "asFound": "Rate",
                    "relevance": "HIGH"
                },
                {
                    "id": "M225513",
                    "name": "Fludarabine phosphate",
                    "relevance": "LOW"
                },
                {
                    "id": "M10212",
                    "name": "Immunosuppressive Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M10201",
                    "name": "Immunologic Factors",
                    "relevance": "LOW"
                },
                {
                    "id": "M20604",
                    "name": "Antirheumatic Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M20942",
                    "name": "Antineoplastic Agents, Alkylating",
                    "relevance": "LOW"
                },
                {
                    "id": "M3820",
                    "name": "Alkylating Agents",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "ANeo",
                    "name": "Antineoplastic Agents"
                },
                {
                    "abbrev": "ARhu",
                    "name": "Antirheumatic Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}